Targeted Medical Pharma, Inc.
TRGM · OTC
12/31/2015 | 12/31/2014 | 12/31/2013 | 12/31/2012 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.02 | 0.21 | -0.05 |
| FCF Yield | -303.08% | 14.58% | -12.13% | -4.82% |
| EV / EBITDA | -3.39 | -4.12 | -6.48 | -5.97 |
| Quality | ||||
| ROIC | 26.62% | 42.48% | 447.48% | -134.88% |
| Gross Margin | 60.17% | 68.84% | 68.72% | 56.12% |
| Cash Conversion Ratio | 0.42 | -0.20 | 0.22 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -18.04% | -0.85% | 2.75% | -1.45% |
| Free Cash Flow Growth | -263.86% | 135.99% | 18.75% | 13.87% |
| Safety | ||||
| Net Debt / EBITDA | -3.13 | -1.69 | -1.27 | -0.50 |
| Interest Coverage | -1.73 | -2.12 | 0.00 | -2.79 |
| Efficiency | ||||
| Inventory Turnover | 22.73 | 17.43 | 5.02 | 6.69 |
| Cash Conversion Cycle | -276.17 | -207.02 | -99.83 | -173.82 |